Sponsor: Ellipses Pharma
A Phase 2 study to evaluate the safety and efficacy of EP0057 in combination with Olaparib in advanced ovarian cancer patients who have:
Cohort 1 – platinum resistant disease and are PARP inhibitor naïve.
Cohort 2 – had at least 2 prior lines of therapy which must include at least 1 line of platinum-based chemotherapy followed by PARP inhibitor maintenance.
For more information please contact the clinical research department: 631-675-5075